title: Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
abstract: OBJECTIVE
  To evaluate factors associated with second remission in dogs with lymphoma retreated with a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) protocol after relapse following initial treatment with a first-line 6-month CHOP protocol.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  95 dogs with lymphoma.
  
  
  METHODS
  Medical records were reviewed. Remission duration was estimated by use of the Kaplan-Meier method. Factors potentially associated with prognosis were examined.
  
  
  RESULTS
  Median remission duration after the first-line CHOP protocol was 289 days (range, 150 to 1,457 days). Overall, 78% (95% confidence interval [CI], 69% to 86%) of dogs achieved a complete remission following retreatment, with a median second remission duration of 159 days (95% CI, 126 to 212 days). Duration of time off chemotherapy was associated with likelihood of response to retreatment; median time off chemotherapy was 140 days for dogs that achieved a complete remission after retreatment and 84 days for dogs that failed to respond to retreatment. Second remission duration was associated with remission duration after initial chemotherapy; median second remission duration for dogs with initial remission duration ≥ 289 days was 214 days (95% CI, 168 to 491 days), compared with 98 days (95% CI, 70 to 144 days) for dogs with initial remission duration < 289 days.
  
  
  CONCLUSIONS
  Findings suggested that retreatment with the CHOP protocol can be effective in dogs with lymphoma that successfully complete an initial 6-month CHOP protocol.
authors.affiliation: The Animal Medical Center, 510 E 62nd St, New York, NY 10065, USA. flory.andy@gmail.com
authors.forename: Andrea B
authors.initials: AB
authors.lastname: Flory
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Rassnick
authors.forename: Hollis N
authors.initials: HN
authors.lastname: Erb
authors.forename: Laura D
authors.initials: LD
authors.lastname: Garrett
authors.forename: Nicole C
authors.initials: NC
authors.lastname: Northrup
authors.forename: Kim A
authors.initials: KA
authors.lastname: Selting
authors.forename: Brenda S
authors.initials: BS
authors.lastname: Phillips
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Locke
authors.forename: John D
authors.initials: JD
authors.lastname: Chretin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone